Deep Breeze to Showcase New Predictive Post-Operative Lung Function Application at WCLC 2011

OR AKIVA, Israel, June 21, 2011 /PRNewswire/ –

Deep Breeze [http://www.deepbreeze.com ], The leader in Vibration
Response Imaging (VRI(TM)) technology, will showcase its new lung imaging
systems embedded with the O-Plan application, at the WCLC
[http://www.2011worldlungcancer.org ] (The 14th World Conference on Lung
Cancer) annual meeting in Amsterdam, The Netherlands, which will take place
on July 3-7, 2011 at the RAI Conference Center (booth 2312).

Deep Breeze’s VRI systems are now integrated with advanced interactive
software tailored specifically for thoracic surgeons; this software enables
the physician to automatically calculate the predicted post-operative (PPO)
lung function for high and low risk lung cancer patients prior to resection
surgery.

The O-Plan application, with radiation-free VRIxp(TM) recordings, can be
implemented as an alternative to nuclear perfusion scans that are performed
prior to lung resections. The VRI O-Plan tool enables regional lung imaging
quantification, which has been shown to be reliably correlative to the
regional distribution of the perfusion. Additionally, following observations
and trials of hundreds of patients, the VRI O-Plan tool has shown highly
accurate post-surgery predictions compared to the VQ Perfusion Scan results
and most importantly, the O-Plan has also shown highly accurate post-surgery
pulmonary function prediction in comparison to actual lung function
parameters (FEV1, DLCO) in patients, a few weeks after lung resection
surgery.

“Our FDA-approved VRIxp(TM) lung imaging system offers an easy and
radiation-free method to automate a calculation that is typically performed
manually by physicians, when considering physiologic data prior to resection
surgery,” said Dr. Miki Nagler, CEO at Deep Breeze. “The procedure can be
performed in the pulmonary function testing lab or directly in the surgeon’s
or oncologist’s office.”

“Predictions based on lung function testing and quantitative breath
sound measurements demonstrated high correlations with quantitative
perfusion estimations and corroborate previously published results,” said
DR. Frank C. Detterbeck, professor of Thoracic Surgery at the Yale
University Medical Center. “Given its simplicity of operation, lack of
radiation and the non-invasive nature of VRIxp testing, it could be a good
alternative to quantitative perfusion scans in preoperative lung resection
assessment.”

Clinical use of the VRI systems with the O-Plan application in Germany,
Canada, Spain, Turkey, Russia, the Czech Republic and China, reveal that
this technique is suitable for wide use in predicting post-operative lung
function in patients with lung cancer.

About Deep Breeze

Founded in 2001, Deep Breeze is a privately-held medical device company
that provides advanced pulmonary imaging with its proprietary patented
technology, Vibration Response Imaging (VRI). The Company has conducted
clinical studies globally to evaluate VRI efficacy in fields such as:
general pulmonology, COPD, CHF, asthma, interventional pulmonology, lung
cancer, lung transplant and critical care patient management.

For additional information, please visit our website:

http://www.deepbreeze.com.

        Contact Information:

        Hagai ben Asher
        Senior Sales Director
        Deep Breeze
        Tel: +972-46188605
        Email: Hagai.benasher@deepbreeze.com

SOURCE Deep Breeze